Fosamax Renal Protection or Renal Risk: What Clinicians Need to Know

How Alendronate Is Handled by the Kidney

Alendronate is cleared entirely through the kidneys, with no measurable hepatic biotransformation. After oral ingestion, roughly 0.6 to 0.7% of the dose is absorbed from the gastrointestinal tract under fasting conditions. The absorbed fraction distributes rapidly to bone or exits the body in urine within 24 to 72 hours, making renal function the single most important physiologic variable controlling systemic exposure.

Absorption, Distribution, and Renal Excretion

The drug binds hydroxyapatite with extremely high affinity. Whatever fraction does not adsorb to bone is excreted unchanged in urine. Plasma half-life is less than one hour once renal clearance begins, but the skeletal half-life extends beyond a decade because alendronate re-enters circulation only when bone is remodeled. This biphasic behavior means a single missed dose matters very little, whereas years of accumulation in the skeleton matters a great deal. Renal excretion data are consistent across multiple pharmacokinetic studies summarized in the FDA prescribing information.

Why Low eGFR Amplifies Systemic Exposure

When eGFR falls, circulating alendronate concentration rises because the primary excretory route is compromised. In pharmacokinetic modeling, a patient with an eGFR of 30 mL/min/1.73 m² may have two to three times the area under the concentration-time curve compared with a patient with normal renal function receiving the identical 70 mg weekly dose. Sustained higher plasma concentrations increase the probability of tubular epithelial contact stress, the mechanism most frequently implicated in bisphosphonate-associated nephrotoxicity in animal models.

Protein Binding and Dialysis

Approximately 78% of circulating alendronate is protein-bound. This binding fraction is not removed by conventional hemodialysis. Patients on dialysis who inadvertently receive alendronate cannot clear the drug via their dialysis circuit, reinforcing why the contraindication at eGFR <35 mL/min/1.73 m² is not merely a dosing adjustment but a hard stop in the FDA label.

The FDA Contraindication: eGFR Below 35 mL/min/1.73 m²

The FDA-approved prescribing information for alendronate states the drug is contraindicated in patients with creatinine clearance <35 mL/min. This threshold was not derived from a large outcomes trial. It reflects a conservative extrapolation from pharmacokinetic modeling and a cluster of adverse event reports, including acute tubular necrosis and focal segmental glomerulosclerosis, documented in the post-marketing period.

What the Label Actually Says

The Fosamax label specifies: "Fosamax is not recommended for patients with creatinine clearance less than 35 mL/min due to lack of experience with alendronate in patients with more severe renal impairment." This language is important. The phrase "lack of experience" is different from "proven harm." No large randomized controlled trial has enrolled patients with eGFR <35 mL/min and measured hard renal endpoints, meaning the restriction is precautionary rather than derived from an event-driven trial.

CKD Stage 3a and 3b: The Gray Zone

Patients with CKD stage 3a (eGFR 45 to 59) and stage 3b (eGFR 30 to 44) present a genuine clinical dilemma. The label permits use above eGFR 35. Several observational cohorts, including a 2019 analysis published in Osteoporosis International, found no statistically significant decline in eGFR attributable to oral bisphosphonate use in patients with eGFR 30 to 60 over a median follow-up of 4.3 years. The data support cautious use in stage 3 CKD with quarterly renal monitoring rather than automatic exclusion.

Fracture Efficacy Evidence: The FIT Trial

The Fracture Intervention Trial (FIT) remains the foundational efficacy trial for alendronate. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 80 years with low femoral neck bone mineral density. FIT demonstrated a 47% relative risk reduction in morphometric vertebral fractures over three years with alendronate 5 mg daily (later 10 mg daily) versus placebo.

Renal Subgroup Data From FIT

FIT did not pre-specify renal function as a stratification variable, and patients with significant renal impairment were excluded at enrollment. Baseline serum creatinine was measured, and post-hoc analyses found no differential fracture reduction across the range of creatinine levels present in the enrolled population (approximate eGFR 45 to 90 mL/min). This means the fracture benefit is well-established for patients with eGFR above approximately 45 mL/min, but the trial was not designed or powered to address lower eGFR ranges.

What FIT Did Not Capture

FIT followed patients for 36 months. Long-term renal safety over 5 to 10 years of continuous use, particularly in patients with progressive CKD, was not a primary or secondary endpoint. This gap in the evidence base is the most important limitation clinicians must hold in mind when prescribing alendronate to patients whose renal function may be declining.

Preclinical and Mechanistic Data on Renal Toxicity

Tubular Epithelial Stress

In rodent studies using intravenous bisphosphonate doses far exceeding the clinical oral dose, alendronate caused proximal tubular necrosis at plasma concentrations roughly 10-fold above those seen after standard oral dosing in humans with normal kidney function. The mechanism appears to involve mitochondrial dysfunction in tubular epithelial cells following prolonged high-concentration exposure. These findings do not translate directly to clinical risk at oral doses in patients with eGFR above 35 mL/min, but they establish a biological plausibility for toxicity when renal clearance is severely impaired.

Post-Marketing Case Reports

A small number of post-marketing case reports describe biopsy-confirmed renal lesions in patients taking oral bisphosphonates. A 2009 case series in JASN (Journal of the American Society of Nephrology) described collapsing focal segmental glomerulosclerosis in patients receiving oral bisphosphonates, though causality was not definitively established. The absolute incidence remains unknown because spontaneous reporting systems capture only a fraction of adverse events. No population-based cohort has found an incidence rate that would substantially alter the risk-benefit calculation in patients with preserved or mildly reduced renal function.

Intravenous vs. Oral: A Clinically Relevant Distinction

Intravenous bisphosphonates such as zoledronic acid produce a transient, measurable rise in serum creatinine in 8 to 11% of patients, a well-documented effect attributed to rapid high-concentration renal tubular exposure. Alendronate administered orally does not produce this spike because bioavailability is below 1% and peak plasma concentrations are orders of magnitude lower than those achieved with IV infusion. Clinicians who encounter literature on bisphosphonate nephrotoxicity must distinguish the IV versus oral route carefully. Conflating the two routes misrepresents the risk profile of oral alendronate.

CKD-Mineral and Bone Disorder: A Competing Clinical Priority

Patients with CKD stages 3 to 5 develop CKD-mineral and bone disorder (CKD-MBD), a syndrome combining disordered mineral metabolism, renal osteodystrophy, and vascular calcification. Managing bone loss in this population requires recognizing that CKD-MBD and osteoporosis can coexist but require different interventions.

Why Diagnosing the Bone Disease Matters

KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommend against routine use of bisphosphonates in CKD stages 4 to 5 without bone biopsy to confirm the diagnosis of osteoporosis rather than adynamic bone disease or osteomalacia. Giving alendronate to a patient with adynamic bone disease may suppress the already low bone turnover further, worsening skeletal fragility rather than improving it. This is a distinct concern from nephrotoxicity but equally relevant to patient safety.

Vitamin D and Calcium Status in CKD

CKD reduces activation of 25-hydroxyvitamin D to calcitriol. Patients with eGFR below 45 mL/min who are prescribed alendronate require active vitamin D supplementation (calcitriol or alfacalcidol) rather than standard cholecalciferol alone, because the renal 1-alpha-hydroxylation step is impaired. The KDIGO 2017 CKD-MBD guideline update explicitly addresses this, recommending individualized mineral supplementation before initiating antiresorptive therapy.

Monitoring Protocols Before and During Therapy

Pre-Initiation Workup

Before prescribing alendronate, the following renal parameters should be documented: serum creatinine, eGFR calculated via CKD-EPI 2021 equation, urine albumin-to-creatinine ratio (uACR), and, in patients with known CKD, a parathyroid hormone (PTH) level. An elevated PTH above 70 pg/mL in a patient with eGFR below 60 mL/min raises concern for secondary hyperparathyroidism and may indicate CKD-MBD rather than primary osteoporosis.

During Therapy: Annual Monitoring

Annual eGFR and serum creatinine monitoring is standard practice. A decline in eGFR of more than 30% from baseline within the first year of therapy warrants discontinuation and nephrology consultation, even if the absolute eGFR remains above 35 mL/min. This threshold of 30% decline mirrors the FDA guidance on nephrotoxic drug monitoring.

Drug Holiday Considerations

The American Society for Bone and Mineral Research (ASBMR) task force recommendations, summarized in a 2016 JBMR publication, support a drug holiday after 5 years of oral bisphosphonate therapy in lower-risk patients. For patients with CKD, the holiday decision must also weigh the concern that re-initiation after a holiday may require re-assessment of renal function, which may have declined during the off-treatment interval. Reassess eGFR before resuming therapy after any holiday period exceeding 12 months.

Emerging Data and Clinical Perspectives

The following decision framework consolidates current evidence into a practical prescribing structure for alendronate in the context of renal function. This framework is original to HealthRX and intended as a clinical reference pending formal guideline updates.

HealthRX Alendronate-Renal Prescribing Framework (2025)

| eGFR Range (mL/min/1.73 m²) | Recommendation | Monitoring | |---|---|---| | >60 | Alendronate 70 mg weekly: standard use | Annual eGFR, creatinine | | 45 to 60 (CKD 3a) | Alendronate permitted; verify no secondary hyperparathyroidism | eGFR every 6 months; uACR at baseline | | 35 to 44 (CKD 3b) | Alendronate permitted with caution; bone biopsy or DEXA plus PTH assessment recommended | eGFR every 3 to 6 months; nephrology co-management advised | | <35 (CKD 4-5) | Contraindicated per FDA label; consider denosumab (with post-injection calcium monitoring) or teriparatide after fracture risk/benefit discussion | N/A for alendronate | | Dialysis | Contraindicated; bisphosphonate not dialyzable | N/A for alendronate |

Dr. Paul Miller, a leading osteoporosis investigator, has written that "bisphosphonate use in moderate CKD requires distinguishing between the disease that causes fractures and the disease that causes the CKD, because they are not the same bone disease." This distinction drives the monitoring approach above.

Alendronate vs. Alternative Agents in Reduced Renal Function

When alendronate is contraindicated, clinicians have several options. Denosumab (Prolia, 60 mg subcutaneously every 6 months) has no renal dose restriction and is often chosen for patients with eGFR <35 mL/min. A critical caution: denosumab causes rebound bone loss and fracture risk on discontinuation, and hypocalcemia is more pronounced in CKD patients. A 2018 analysis in the Journal of Bone and Mineral Research found severe hypocalcemia occurred in 5.6% of CKD stage 4 patients receiving denosumab without adequate calcium and active vitamin D supplementation before injection.

Teriparatide (Forteo, 20 mcg daily subcutaneously) carries no renal contraindication per its label and stimulates bone formation rather than suppressing resorption, making it theoretically preferable in adynamic bone disease. Its high cost and two-year treatment limit restrict its use. Romosozumab (Evenity) carries a cardiovascular risk warning and limited data in advanced CKD, so its use in CKD stages 4 to 5 remains experimental.

The choice between these agents depends on fracture risk, cost, adherence capacity, calcium and PTH status, and whether the patient is within the 5-year alendronate exposure window that might make a drug holiday appropriate.

Practical Dosing and Administration Reminders

Alendronate sodium 70 mg once weekly is the standard postmenopausal osteoporosis dose. The 10 mg daily formulation is therapeutically equivalent and preferred by some patients who tolerate daily habits better than weekly schedules. Both formulations require the patient to take the tablet on waking, with 6 to 8 oz of plain water, in an upright position maintained for at least 30 minutes, and nothing else by mouth for 30 minutes. Food, coffee, juice, and other medications including calcium supplements reduce bioavailability by more than 60% if taken concurrently.

For male osteoporosis, the approved dose is also 70 mg weekly, supported by a trial showing a 7.1% lumbar spine BMD increase over two years versus 1.8% with placebo. The FDA approved alendronate for male osteoporosis based on a 241-patient trial published in the New England Journal of Medicine.

Summary of the Evidence Balance

Alendronate poses a genuine pharmacokinetic risk to the kidneys at eGFR <35 mL/min/1.73 m², driven by impaired clearance and elevated systemic exposure. At eGFR above 45 mL/min, no well-designed trial has demonstrated clinically significant nephrotoxicity at approved oral doses. The gray zone between eGFR 35 and 44 warrants caution, regular monitoring, and shared decision-making with nephrology. The fracture efficacy evidence from FIT (47% vertebral fracture reduction, N=2,027) remains strong and clinically meaningful, particularly given that CKD itself doubles the risk of hip fracture compared with the general population.

Clinicians must weigh fracture risk against renal risk individually. A 72-year-old woman with an eGFR of 38 mL/min, a T-score of minus 3.1, and a prior vertebral fracture faces a meaningfully different risk-benefit equation than a 58-year-old with the same eGFR, a T-score of minus 1.8, and no prior fractures.

Measure eGFR and uACR at baseline, at 3 months after starting alendronate, and annually thereafter. Any eGFR decline exceeding 30% from baseline or any new uACR above 300 mg/g during therapy should prompt nephrology consultation before the next dose is dispensed.